Apthera Inc.
This article was originally published in Start Up
Executive Summary
Apthera was formed two years ago to further develop NeuVax, an investigational therapeutic cancer vaccine. NeuVax, which combines the T-cell peptide E75 with GM-CSF, is poised to enter Phase III testing in early-stage breast cancer patients to prevent recurrence of the disease and is also in early trials in prostate cancer,
You may also be interested in...
RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product
Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.
RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product
Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.
Amping Up Dendritic Cells
Researchers are looking for ways to better stimulate dendritic cells (DCs, the antigen presenting cells that initiate and control many aspects of the immune response) in the hopes of creating potent vaccines against tumors and infectious diseases. A recent paper highlights progress on the DC targeting front using a DNA vaccine strategy, but is also a reminder that the immunotherapy field has a long way to go.